Why We Walk: Research

The ALS Association is the only ALS non-profit organization to support people with ALS on every front — care services, research and advocacy. Find out how money raised by Walk teams all over the country positively impact these important mission priorities.

With your support, The ALS Association’s collaborative and global approach to funding research continues to lead to significant discoveries by top ALS scientists all around the globe. With the world’s largest ALS non-profit research program, The Association is currently active in more than 150 laboratories across the globe. In The Association’s history since 1985, we have committed over $128 million to research. Due to the huge funding boost from generous donors during the ALS Ice Bucket Challenge (IBC), so far we have committed over $84 million to research alone, not including investments in the other core pillars of The Association.

We feel privileged with this great responsibility to spend these dollars wisely, transparently and in ways that make the most impact on the fight against this disease. We are committed to maximizing all donations from the ALS IBC and beyond by partnering with other organizations to fund research, along with tremendous efforts by our ALS advocates and volunteers across the country. It is important to keep up the momentum to contribute to funding the most promising ALS research all over the world!

Here are some research progress supported by The ALS Association made possible by you!

  • Advanced ALS research to better understand the disease and contributed to the knowledge base of ALS research in the scientific community, where results were published in top scientific journals.
  • Invested in numerous ALS clinical trials through our Clinical Trial Pilot Program, facilitated partnerships between academia and industry to propel ideas from the lab into clinical trials and invested in clinical trial infrastructure to ensure trials are carried out at the highest level.
  • The Association announced spending decisions to ignite 9 research strategic initiatives, including 2 new strategic initiatives this past year — ALS ONE-MAP and NeuroLINCS — to advance progress towards finding treatments and a cure for ALS.
  • Supported global collaborations including Project MinE that led to the discovery of 3 new ALS genes — KIF5A, NEK1, and C21orf2 — leading us closer to identifying novel therapeutic targets for ALS.
  • Funded 6 new bright, young scientists through our Milton Safenowitz Postdoctoral Fellowship Program and 2 new Clinician Scientists through fellowship awards in partnership with the American Academy of Neurology (AAN).
  • In partnership with Prize4Life, awarded 2 ALS Assistive Technology Challenge winners — Donders Institute for Brain, Cognition and Behavior from the Netherlands and Pison Technology from Massachusetts — that developed flexible, accessible technology to help people living with ALS communicate with ease.

Learn more about Research.

Thank You to Our National Sponsors